Germany · Delayed Price · Currency is EUR Bayer Aktiengesellschaft Earnings Call Transcripts
Fiscal Year 2026
-
A five-year strategy is on track, emphasizing margin expansion, cost savings, and a robust innovation pipeline with major product launches planned through 2029. Market dynamics remain stable in North America and Brazil, while global uncertainties and supply chain pressures persist. Legal progress on glyphosate litigation and new biofuel partnerships further shape the outlook.
-
Q1 2026 saw 4% sales growth and higher EPS, driven by Crop Science and Consumer Health, while Pharma remained flat. Litigation settlements and regulatory clarity efforts progressed, and the full-year outlook was confirmed despite FX and geopolitical risks.
-
Q1 2026 saw 4% sales growth and a 13% rise in core EPS, driven by strong Crop Science performance and non-recurring licensing income. Litigation-related cash outflows weighed on free cash flow, but full-year guidance is reaffirmed amid ongoing regulatory and geopolitical risks.
-
The AGM highlighted strong financial performance, progress on debt reduction, and a continued focus on litigation containment and operational transformation. Shareholders approved all management proposals, including a minimum dividend and new board appointments, while voicing concerns on ESG, product safety, and governance.
-
A major class settlement agreement was reached to resolve most U.S. glyphosate litigation, with capped payments over 21 years and increased provisions to EUR 11.8 billion. The deal, pending court approval and influenced by a Supreme Court case, aims to provide closure and strategic flexibility while maintaining strong R&D and financial stability.
-
OCEANIC-STROKE phase III showed asundexian significantly reduced recurrent ischemic and disabling strokes without increasing major or minor bleeding, with consistent benefits across all subgroups and stroke etiologies. The drug's safety and efficacy profile positions it as a potential new standard for secondary stroke prevention.
-
Strong growth in new products and a rejuvenated pipeline are driving a turnaround, with mid-single-digit growth expected from 2027. Key launches in oncology, cardiovascular, and women's health, along with increased R&D productivity and operational agility, position the business for sustained margin expansion and innovation.
Fiscal Year 2025
-
Delivered on upgraded 2025 guidance with EUR 45.5B sales and EUR 4.91 core EPS, while managing major litigation provisions and advancing transformation. 2026 outlook anticipates stable sales and EPS, negative free cash flow due to litigation, and continued investment in growth drivers.
-
Delivered on upgraded 2025 guidance with EUR 45.5B sales and EUR 4.91 core EPS, while implementing cost-saving measures and advancing litigation settlements. 2026 outlook anticipates stable core EPS, negative free cash flow due to litigation, and continued transformation across all divisions.
-
Q3 2025 saw modest sales growth and strong performance from new Pharma launches, offset by FX headwinds and increased litigation provisions. Crop Science and Pharma are on track for full-year targets, while Consumer Health faces continued market challenges, especially in the U.S. and China.
-
Sales grew 1% year-over-year in adjusted terms, with core EPS up and net debt down. Litigation provisions increased, and FX headwinds persist. Pharma launches and portfolio streamlining drive future growth, while Consumer Health faces market challenges.
-
Q2 2025 saw modest sales growth, strong Pharma performance, and significant litigation provisions. Guidance for 2025 was raised for sales and earnings, with stable margins expected despite FX and market headwinds. Litigation settlements and cost-saving initiatives remain key priorities.
-
Sales remained flat in H1 2025, with Q2 net sales up 1% year-over-year in adjusted terms but down 4% as reported due to FX headwinds. Litigation provisions and settlements impacted results, while Pharma and Crop Science showed resilience. Guidance for 2025 was raised on sales and earnings.
-
Aims to become the top global consumer health company by 2030, focusing on innovation, omnichannel growth, and expanding in high-potential markets like Asia-Pacific. Financial resilience, portfolio optimization, and science-backed brands drive strategy, with no current plans for divestment.
-
Seeds and Traits are set for robust growth, while Crop Protection faces margin pressure but is offset by innovation and new value pools. The five-year plan targets over EUR 1 billion EBITDA improvement, EUR 3.5 billion in incremental sales, and a mid-20s margin by 2029, with strong cash flow and enhanced resilience.
-
Q1 2025 saw flat group sales, with crop science declines offset by pharma and consumer health growth. Core EPS was EUR 2.49, and free cash flow improved year-over-year. Guidance for 2025 is confirmed despite FX and tariff risks, with strong pharma launches and ongoing cost management supporting outlook.
-
Q1 2025 saw flat sales overall, with Pharmaceuticals and Consumer Health growth offsetting Crop Science declines. Litigation, regulatory, and FX risks persist, but full-year guidance is reaffirmed and debt reduction remains a priority.
-
The meeting addressed 2024’s mixed financial results, ongoing U.S. litigation risks, and major organizational transformation. Shareholders approved all management proposals, including a minimum dividend, authorized capital for litigation flexibility, and continued virtual meetings.
-
The conference highlighted strong growth from new launches like Nubeqa and Kerendia, resilience in core businesses, and a robust late-stage pipeline. Strategic cost management and a new operating model are driving productivity, while patent expirations and biosimilar competition are being actively managed.
Fiscal Year 2024
-
2024 results met revised guidance with Pharmaceuticals outperforming, while Crop Science faced margin and sales pressure. 2025 is expected to be challenging, with flat sales, lower earnings, and continued focus on cost savings, debt reduction, and operational transformation.
-
Q3 2024 saw modest group sales growth, with pharma and consumer health offsetting crop science declines. EBITDA and EPS were down due to impairments and FX headwinds, but full-year targets remain on track. Regulatory, litigation, and FX risks persist into 2025.
-
Q3 2024 saw modest group sales growth, with Pharmaceuticals and Consumer Health offsetting Crop Science declines. Litigation, regulatory delays, and FX headwinds weighed on results, but cost-saving and efficiency measures are on track, with 5,500 jobs cut and full-year targets reaffirmed.
-
FINEARTS-HF phase III trial showed Finerenone significantly reduced cardiovascular death and heart failure events in patients with mildly reduced or preserved ejection fraction, with consistent benefits and a favorable safety profile. Pooled FINE-HEART analysis confirmed efficacy across cardiorenal outcomes, supporting its use.
-
Q2 2024 saw modest sales growth and improved free cash flow, with strong momentum in pharma and consumer health offsetting crop science headwinds. Full-year guidance is reaffirmed, though Crop Science is expected at the lower end due to glyphosate and pricing pressures.
-
Q2 2024 saw 3% adjusted sales growth and improved free cash flow, despite margin pressure and a 23% drop in core EPS. Pharmaceuticals and consumer health showed strong momentum, while crop science faced market headwinds. Full-year guidance is reaffirmed.